Axillary hyperhidrosis Pipeline 2025: Pioneering Clinical Developments by 3+ Global Leaders - DelveInsight | Highlighting GlaxoSmithKline, Medytox, Theravidam, Candesant Biomedical

DelveInsight's, "Axillary Hyperhidrosis - Pipeline Insight, 2025," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Axillary Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
With Axillary hyperhidrosis becoming increasingly prevalent worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and certain cancers, the need for safer and more effective treatments is rising. DelveInsight reports that the Axillary hyperhidrosis pipeline includes 3+ pharmaceutical and biotech companies actively developing 3+ therapeutic candidates for this condition. These therapies are in various stages of clinical and preclinical development, reflecting strong innovation and a commitment to tackling a significant public health challenge.

DelveInsight's "Axillary Hyperhidrosis Pipeline Insight 2025" provides a comprehensive analysis of the current R&D landscape, including clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report is an essential resource for stakeholders-such as researchers, healthcare investors, and decision-makers-seeking insights into the evolving Axillary hyperhidrosis therapeutics market and the breakthroughs shaping its future.

Explore the Cutting-Edge Landscape of Axillary hyperhidrosis Drug Development [https://www.delveinsight.com/report-store/axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Key Takeaways from the Axillary hyperhidrosis Pipeline Report

*
DelveInsight's Axillary Hyperhidrosis pipeline report highlights a dynamic landscape with more than three active companies developing multiple therapeutic candidates for the treatment of axillary hyperhidrosis.

*
In June 2024, the FDA approved Sofdra (sofpironium bromide) topical gel for treating primary axillary hyperhidrosis in patients aged nine and older. Sofdra, an anticholinergic, selectively targets M3 muscarinic receptors in sweat glands to reduce sweat production. This approval represents the first new chemical entity specifically indicated for primary axillary hyperhidrosis, providing a convenient, once-daily, self-administered option for patients who previously had limited treatments.

*
In April 2023, the FDA cleared the Brella SweatControl Patch for adults with primary axillary hyperhidrosis. This single-use, in-office device from Candesant Biomedical employs targeted alkali thermolysis (TAT) technology, generating localized heat through interaction with sweat to decrease gland activity. A single three-minute application can offer sweat reduction for up to four months.

*
Key companies such as GlaxoSmithKline, Medytox, Theravidam, Candesant Biomedical, and others are actively pursuing new therapies to enhance the treatment landscape for axillary hyperhidrosis. Promising pipeline candidates include Sofpironium bromide, ET-01, DMT410, among others.

Axillary hyperhidrosis Overview:

Hyperhidrosis is a disorder characterized by excessive sweating, often starting in childhood or adolescence and sometimes persisting throughout life. Primary hyperhidrosis most commonly affects the palms, soles, underarms (axilla), groin, and area beneath the breasts. The precise cause of axillary hyperhidrosis remains unclear, but it is associated with overactive stimulation of sweat glands by the nervous system. While the sweat glands enlarge and produce excess sweat, this is viewed as a secondary effect. Sweating can be triggered by factors such as anxiety, stress, pain, physical activity, caffeine, or nicotine. In some instances, excessive sweating may affect the entire body or lead to persistent facial redness. The skin in affected regions may appear discolored, soft, cracked, or scaly. Genetics also play a role, with up to 30% of cases reporting a family history. The severity of hyperhidrosis ranges from occasional to continuous daily sweating.

Download the Axillary hyperhidrosis sample report to know in detail about the Axillary hyperhidrosis treatment market [https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Axillary hyperhidrosis Pipeline Analysis

The Axillary hyperhidrosis pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Axillary hyperhidrosis Market.

*
Categorizes Axillary hyperhidrosis therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Axillary hyperhidrosis drugs under development based on:

*
Stage of development

*
Axillary hyperhidrosis Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Axillary hyperhidrosis Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Axillary hyperhidrosis Licensing agreements

*
Funding and investment activities supporting future Axillary hyperhidrosis market advancement.

Unlock key insights into emerging Axillary hyperhidrosis therapies and market strategies here: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Axillary hyperhidrosis Emerging Drugs

*
Sofpironium bromide: Brickell Biotech Inc.

Sofpironium bromide is an innovative compound under development in the U.S. as a potential once-daily topical therapy for primary axillary hyperhidrosis (excessive underarm sweating). This retro-metabolically engineered anticholinergic works by targeting M3 acetylcholine receptors, aiming to decrease sweat production.

*
ET-01: Eirion Therapeutics

ET-01 is a topical botulinum therapy under development designed to reduce the pain, bruising, and bleeding associated with injectable botulinum treatments. It employs a nanoemulsion-based transdermal delivery system to facilitate absorption of the large botulinum molecule through the skin. ET-01 is currently being evaluated in Phase 2 clinical trials for axillary hyperhidrosis.

*
DMT410: Dermata Therapeutics LLC pipeline

DMT410 represents the second program combining the DMT400 regimen with botulinum toxin. Dermata Therapeutics has conducted a Phase 1 proof-of-concept study evaluating DMT410 alongside BOTOX Registered for treating primary axillary hyperhidrosis. The therapy was generally well tolerated, with most participants showing a reduction in sweating similar to that seen with standard BOTOX Registered injections.

Axillary hyperhidrosis Pipeline Therapeutic Assessment

Axillary hyperhidrosis Assessment by Product Type

- Mono

- Combination

- Mono/Combination

Axillary hyperhidrosis By Stage

- Late-stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Axillary hyperhidrosis Assessment by Route of Administration

- Oral

- Parenteral

- Intravenous

- Subcutaneous

- Topical

Axillary hyperhidrosis Assessment by Molecule Type

- Recombinant fusion proteins

- Small molecule

- Monoclonal antibody

- Peptide

- Polymer

- Gene therapy

Download sample pages to get an in-depth assessment of the emerging Axillary hyperhidrosis therapies and key Axillary hyperhidrosis companies [https://www.delveinsight.com/sample-request/axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Axillary hyperhidrosis Current Treatment Patterns

4. Axillary hyperhidrosis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Axillary hyperhidrosis Late-Stage Products (Phase-III)

7. Axillary hyperhidrosis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Axillary hyperhidrosis Discontinued Products

13. Axillary hyperhidrosis Product Profiles

14. Axillary hyperhidrosis Key Companies

15. Axillary hyperhidrosis Key Products

16. Dormant and Discontinued Products

17. Axillary hyperhidrosis Unmet Needs

18. Axillary hyperhidrosis Future Perspectives

19. Axillary hyperhidrosis Analyst Review

20. Appendix

21. Report Methodology

Request the sample PDF to get detailed insights about the Axillary hyperhidrosis pipeline reports offerings [https://www.delveinsight.com/report-store/axillary-hyperhidrosis-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=axillary-hyperhidrosis-pipeline-2025-pioneering-clinical-developments-by-3-global-leaders-delveinsight-highlighting-glaxosmithkline-medytox-theravidam-candesant-biomedical]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.